COPENHAGEN, Denmark, June 7, 2026
Antag Therapeutics presented positive Phase 1 clinical results and new preclinical findings for AT7687, its first-in-class glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist, at the American Diabetes Association (ADA) 2026 Scientific Sessions. The data demonstrated a favorable safety and tolerability profile, confirmed once-weekly dosing potential, and provided additional evidence supporting AT7687 as a promising combination therapy candidate for obesity and cardiometabolic diseases.
Phase 1 Trial Demonstrates Safety and Target Engagement
The randomized, placebo-controlled Phase 1 study enrolled 102 participants and evaluated the safety, pharmacokinetics, and pharmacodynamics of AT7687 in healthy volunteers with and without obesity. The investigational therapy was well tolerated across both single ascending dose and multiple ascending dose cohorts, with no severe or serious adverse events reported. Importantly, researchers observed no gastrointestinal tolerability signals, a key differentiator in the obesity treatment landscape where GI side effects often limit treatment adherence. Pharmacokinetic analyses showed dose-proportional exposure, low variability between participants, and characteristics supportive of once-weekly subcutaneous administration. Evidence of target engagement was observed across all dose levels tested, reinforcing the therapeutic potential of GIP receptor antagonism.
Combination Data Show Enhanced Weight Loss and Metabolic Benefits
Antag also presented preclinical data from a study evaluating AT7687 combined with cagrilintide, a dual amylin and calcitonin receptor agonist, in obese insulin-resistant non-human primates maintained on a high-fat diet. After 42 days of treatment, the combination therapy achieved 12.2% body weight reduction, compared with 7.8% weight loss with cagrilintide alone. The combination also produced significantly improved insulin sensitivity, increasing glucose disappearance rates by 18.9%, while cagrilintide monotherapy showed a slight decline. Researchers reported the greatest reduction in body fat percentage with the combination regimen, suggesting that GIPR antagonism may contribute additional metabolic benefits beyond appetite suppression alone.
Advertisement
Potential Foundation for Next-Generation Obesity Treatments
The company believes the latest clinical and preclinical findings strengthen the case for AT7687 as a differentiated obesity therapy capable of supporting personalized combination treatment strategies. The absence of significant gastrointestinal side effects and the potential to administer the therapy without dose titration could provide important advantages for long-term patient adherence. Antag plans to initiate a Phase 2a clinical trial of AT7687 in mid-2026 to further evaluate its efficacy and safety in people living with obesity. As the obesity treatment market continues to evolve toward combination therapies targeting multiple metabolic pathways, AT7687 could emerge as a valuable partner therapy for future next-generation obesity and cardiometabolic disease treatments.
Source: Antag Therapeutics press release
